Price
No data yet.
Social Signal Score
Analyst Ratings
33 analystsRevenue
$1.06B+279.12%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joseph Hogan
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 20,435
- Beta
- 1.64
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 4.50
Financials
Revenue
$1.06B+279.1%Net Income
$108.29M+110.8%EBITDA
$90.53M+31.2%Free Cash Flow
$223.54M+426.2%EPS (diluted)
$1.52+141.3%Shares Outstanding (diluted)
71.63M-12.1%Operating Expenses
$564.70MCash & Debt
$1.10BReturn of Capital
$31.20MRevenue by Segment (annual)
$4.03BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.03B | $410.35M | $5.66 |
| 2024 | $4.00B | $421.36M | $5.63 |
| 2023 | $3.86B | $445.05M | $5.82 |
| 2022 | $3.73B | $361.57M | $4.62 |
| 2021 | $3.95B | $772.02M | $9.78 |
| 2020 | $2.47B | $1.78B | $22.55 |
| 2019 | $2.41B | $442.78M | $5.57 |
| 2018 | $1.97B | $400.24M | $5.00 |
| 2017 | $1.47B | $231.42M | $2.89 |
| 2016 | $1.08B | $189.68M | $2.38 |
| 2015 | $845.49M | $144.02M | $1.80 |
| 2014 | $761.65M | $145.83M | $1.81 |
| 2013 | $660.21M | $64.30M | $0.80 |
| 2012 | $560.04M | $58.69M | $0.73 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ALGN's reported EPS growth of 17.1% a year over 13 years.
- EPS in 5 years
- $12.46
- Implied price
- $348.75
- Return from $143.74
- 19.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $173.39 — today's price is already 17.1% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 20 | 24 | 28 | 32 | 36 |
|---|---|---|---|---|---|
| 7.1% | 2.1% | 5.9% | 9.2% | 12.2% | 14.8% |
| 12.1% | 6.9% | 10.8% | 14.3% | 17.4% | 20.2% |
| 17.1% | 11.6% | 15.8% | 19.4% | 22.6% | 25.5% |
| 22.1% | 16.4% | 20.7% | 24.5% | 27.9% | 30.9% |
| 27.1% | 21.2% | 25.7% | 29.6% | 33.1% | 36.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
99+79.70%Social Signal Score
Mentions (19)
- News (RSS)seekingalpha·12h ago·Neutral
Align Technology hit as appeals court revives dental aligners antitrust claims
View source ↗ - News (RSS)zerohedge·20h ago·Neutral
…ed and elevated spending on AI infrastructure (Alphabet unchanged, Amazon -0.1%, Apple -0.2%, Meta -0.2%, Microsoft +0.4%, Tesla -0.3%) Align Technology Inc. shares (ALGN) are down 2.8% after Evercore ISI downgraded the medical-device company to inline from outperform, writing that “the dental macro picture has meaningfully weakened.” Alvotech shares (ALVO) jump 8% after the US FDA approved additional US manufacturing capacity for Simlandi, the biotech’s biosimilar to Humira. CH Robinson Worldwi…
View source ↗ - Newszacks.com·3d ago·Neutral
Will Align Technology (ALGN) Beat Estimates Again in Its Next Earnings Report? Align Technology (ALGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
View source ↗ - Newszacks.com·3d ago·Positive
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
View source ↗ - Newsbusinesswire.com·7d ago·Neutral
…lign Technology Launches “SHIFT Happens” U.S. Campaign to Educate Adults About Lifelong Tooth Movement TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the launch of SHIFT Happens, a new consumer campaign designed to help Invisalign-tr…
View source ↗ - News (RSS)yahoo·18d ago·Neutral
Align Technology Sees Invisalign Growth Runway Despite Consumer Headwinds
View source ↗ - Newsmarketbeat.com·18d ago·Neutral
Align Technology Sees Invisalign Growth Runway Despite Consumer Headwinds Align Technology NASDAQ: ALGN sees continued growth potential for Invisalign clear aligners in the United States and internationally despite a challenging consumer environment, Chief Financial Officer John Morici said during a Baird investor conference.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Align Technology, Inc. (ALGN) Presents at 2026 Global Healthcare Conference Transcript Align Technology, Inc. (ALGN) Presents at 2026 Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·21d ago·Neutral
Should You Continue to Hold ALGN Stock in Your Portfolio? Align Technology expands Invisalign and digital dentistry adoption as iTero gains traction, but weak capital spending and currency volatility remain risks.
View source ↗ - News (RSS)investing·27d ago·Positive
Align Technology options: bullish $220 call dominates flow as ALGN stock slides
View source ↗ - Newsbusinesswire.com·35d ago·Negative
Quentin Blackford to Join Align Technology Board of Directors TEMPE, Ariz. & SAN JOSE, Calif.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that its Board of Directors has appointed Quentin Blackford, President and Chief Executive Offi…
View source ↗ - News (RSS)investing·45d ago·Neutral
Aligned Launches $ALIGN, the Native Token of Its Full Ethereum Stack
View source ↗ - News (RSS)zerohedge·47d ago·Neutral
7 Federal Agencies & Big Pharma Quietly Built A Pandemic-Industrial Complex 7 Federal Agencies & Big Pharma Quietly Built A Pandemic-Industrial Complex Authored by Jon Fleetwood via substack, Nearly 14 years before COVID-19, HHS created the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) and centralized federal health, biomedical, regulatory, homeland-security, and military functions around a government-directed countermeasure pipeline. Creating what this website refers to as
View source ↗ - Newsgurufocus.com·49d ago·Positive
Align Technology Inc (ALGN) Stock Down 5.6% -- Now Undervalued? GF Score: 89/100 On August 17, 2026, Align Technology Inc (ALGN) shares fell 5.6%, bringing the current price to $171.16. The stock has experienced a 52-week range of $122.00 to
View source ↗ - News (RSS)seekingalpha·49d ago·Positive
Align Technology: DCF Signals Overvaluation Despite Long-Term Growth Potential
View source ↗ - News (Marketaux)seekingalpha.com·49d ago·Positive
Align Technology: DCF Signals Overvaluation Despite Long-Term Growth Potential I am assigning a hold rating to Alig[+320 characters]
View source ↗ - Newszacks.com·52d ago·Positive
Should Investors Buy Align as Growth Meets Valuation and Demand Risks? ALGN's record Clear Aligner growth and global adoption support the bull case, but demand softness and scanner pricing pressure keep investors cautious.
View source ↗ - News (RSS)financialpost·55d ago·Neutral
Align Technology Prevails in China Patent Infringement Action Against Angelalign SAN JOSE, Calif. & TEMPE, Ariz. — Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, today announced that the Jinan Intermediate People’s Court in China issued a judgment in favor of Align in a patent infringement action against Angelalign Technology’s […]
View source ↗ - Newsbusinesswire.com·55d ago·Neutral
Align Technology Prevails in China Patent Infringement Action Against Angelalign SAN JOSE, Calif. & TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, today announced that the Jinan Intermediate People's Court in China issued a judgment in favor of Align in a patent infringement action against Angelalign Technology's operating subsidiaries in China
View source ↗
Earnings
Wed, Oct 28(in 3 weeks)
Consensus estimate $2.80 per share
Typical surprise +7.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$2.64 vs $2.62beat
- Wed, Apr 29$2.58 vs $2.30beat
- Wed, Feb 4$3.29 vs $2.99beat
- Wed, Oct 29$2.61 vs $2.40beat
- Wed, Jul 30$2.49 vs $2.57miss
- Wed, Apr 30$2.13 vs $1.99beat
Estimates and results for ALGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ALGN officers and directors.
- Bought
- $1.0m
- Sold
- $1.5m
2 trades
1 trade
- Morici Johnsold
- Hogan Joseph Mbought
- Coletti Julie Annbought
97 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Oct 22, 2025 (41d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Sep 15, 2025 (42d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed May 8, 2025 (30d later)Sell$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Mar 28, 2025 (31d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Mar 7, 2025 (9d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 8, 2024 (29d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 8, 2024 (29d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jun 8, 2024 (19d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (22d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 5, 2024 (26d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2023 (33d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Nov 11, 2023 (15d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (37d later)Buy$1,001 - $15,000
- Daniel Scott Sullivansenate · AK · disclosed Sep 22, 2023 (31d later)Sell$1,001 - $15,000
- Daniel Scott Sullivansenate · AK · disclosed Sep 18, 2023 (27d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 6, 2023 (8d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Aug 7, 2023 (10d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 11, 2023 (15d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 12, 2023 (39d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.